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Abstract 
Background: Tiotropium (TIO) is a well-established bronchodilator, LAMA (long-acting anticholinergic), for the 
treatment of moderate to very severe chronic obstructive pulmonary disease (COPD). Clinical evidence suggests that 
tiotropium is superior to usual non-LAMA care (UC) but may also have benefits compared to other LAMAs in prevent-
ing and limiting the effects of severe exacerbations. The primary objective of this study was to undertake a cost-effec-
tiveness analysis of adding tiotropium to usual care versus usual care alone. A secondary objective was to assess the 
cost-effectiveness of tiotropium compared to glycopyrronium (GLY), another LAMA. The study was conducted with a 
Swedish setting in mind.
Methods: A Markov cohort model, incorporating the effects of exacerbations, was populated with efficacy data from 
the UPLIFT and SPARK trials and epidemiological data relevant for a Swedish patient population. Treatment efficacy of 
tiotropium was modelled as a lowering of the risk of exacerbations and as a slow-down of overall disease progression. 
The model followed patients over their remaining life-time.
Results: The base case analysis showed that patients treated with tiotropium gained 0.07 quality-adjusted life years 
(QALYs) compared to usual care alone at an incremental cost of SEK 15,041, resulting in a cost per QALY gained of SEK 
224,850. Compared to glycopyrronium the QALY gained was estimated to 0.23 QALYs in favour of tiotropium at an 
incremental cost of SEK 2423, yielding a cost per QALY gained of SEK 10,456. The results were mainly driven by differ-
ences in the risk of severe exacerbations.
Conclusion: At the current implicit willingness-to-pay (WTP) per QALY threshold in Sweden, the results from this 
study indicate that tiotropium is a highly cost-effective intervention when added to usual non-LAMA care in the treat-
ment of moderate to very severe COPD in Sweden. In addition, tiotropium is a highly cost-effective intervention when 
compared to glycopyrronium monotherapy.
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Background
Chronic obstructive pulmonary disease (COPD) is one of 
the most common chronic diseases worldwide and it is a 
major cause of morbidity and mortality. The prevalence 
of COPD in the total adult population is reported to be 
in the range of 5–10 % [1–4]. This rather high prevalence 
translates into a high burden of illness. A study measur-
ing costs of COPD in Sweden in 2010, estimated the total 
costs of COPD to be €1.5 billion annually [5]. COPD 
exacerbations, which are defined as “acute and sustained 
worsening of the patient’s respiratory symptoms beyond 
normal day-to-day variations that result in an increased 
need for medication […]”, are important drivers of COPD-
related costs [6]. Studies from the US and the UK have 
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shown that exacerbations are the most common rea-
sons for hospitalisation of COPD patients [7, 8] and that 
hospitalisations, in turn, stand for 54  % of direct COPD 
costs [9]. Furthermore, exacerbations have been shown 
to increase mortality [10, 11] and decrease health-related 
quality of life [12, 13] in COPD patients.
Pharmacologic therapy for COPD include inhaled cor-
ticosteroids (ICS) and long-acting bronchodilators such 
as LABAs (long-acting β2-agonists) or LAMAs (long-
acting anticholinergics), which are recommended thera-
pies for patients with moderate to very severe COPD [6]. 
In Sweden monotherapy with LAMAs (e.g. tiotropium 
or glycopyrronium) is the first-line treatment. Alter-
natively, LABAs (e.g. salmeterol or indacaterol) can be 
considered, either as monotherapy or as add-on therapy 
[14]. LAMA/LABA combination inhalers (e.g. glycopyr-
ronium +  indacaterol) are available, but have restricted 
reimbursement to patients who have not achieved ade-
quate effect from monotherapy [15]. From a Swedish 
perspective, combination therapies are therefore not rel-
evant comparators to LAMA and LABA monotherapies. 
Inhaled corticosteroid therapy is only considered in com-
bination with LABA therapy for patients with severe or 
very severe COPD [14].
Numerous studies have shown that regular use of 
inhaled LAMAs, LABAs and corticosteroids can lower 
the incidence and effect of exacerbations [16]. In a 4-year, 
randomized, double-blind trial (UPLIFT) with 5993 
patients, tiotropium significantly improved lung func-
tion, in terms of forced expiratory volume in 1 s (FEV1), 
and lowered the risk of exacerbations when added to 
usual non-LAMA care (placebo), compared to usual non-
LAMA care alone [17].
Evidence from recent studies also suggest that tiotro-
pium is superior to both once-daily [18] and twice-daily 
[19] administered LABAs in preventing exacerbations. 
Furthermore, in a recent head-to-head trial (SPARK), 
patients treated with tiotropium had lower rates of severe 
exacerbations (i.e. those leading to hospitalisation) than 
patients treated with glycopyrronium [20]. All in all, the 
evidence to date suggests that tiotropium is superior to 
usual non-LAMA care (UPLIFT) in terms of preserving 
overall lung function and in preventing exacerbations, 
but also that tiotropium performs better than glycopyr-
ronium (SPARK) in terms of preventing severe exacer-
bations. Since exacerbations are key drivers of costs and 
morbidity in COPD, this new data ensures a more valid 
comparison of existing treatment alternatives.
Even though a treatment shows a positive clinical 
profile it is important to ensure that the potential gains 
in terms of improved health for the patient come at an 
acceptable cost to the payers of health care. Today, the 
standard approach to analyse this is by performing a 
cost-effectiveness analysis. Tiotropium has been shown 
to be a cost-effective treatment compared to usual care in 
the management of COPD in a number of countries [21]. 
However, such an assessment has not been conducted 
for Sweden. As such, the main objective of this study 
was to carry out a cost-effectiveness analysis on adding 
tiotropium to usual care versus usual care alone from 
a Swedish perspective. Furthermore, evidence on the 
cost-effectiveness of tiotropium versus other LAMAs is 
scarce. However, with the publication of the SPARK trial, 
comparing tiotropium and glycopyrronium head-to-
head, such an analysis has now become possible. As such, 
a secondary objective was to assess the cost-effectiveness 
of tiotropium compared to glycopyrronium based on the 
SPARK trial.
UPLIFT and SPARK trials
UPLIFT (ClinicalTrials.gov, NCT00144339) [17] was 
a randomised, double-blind, placebo-controlled study, 
investigating the efficacy of tiotropium when added to 
non-LAMA usual care (placebo) compared to placebo 
alone. A total of 5993 patients aged 40  years or more 
(mean age 65 ± 8 years), with a forced expiratory volume 
in 1 s (FEV1) of 70 % or less after bronchodilation and a 
ratio of FEV1 to forced vital capacity (FVC) of 70  % or 
less, were studied over a 4 year period. Co-primary end 
points were the rate of decline in mean FEV1 before and 
after bronchodilation beginning on day 30. Secondary 
end points were, among other things, rates of exacerba-
tions, measures of FVC, changes in St. George’s Respira-
tory Questionnaire (SGRQ) responses (a disease-specific 
health-related quality of life instrument) and mortality. 
The main findings were that mean absolute improve-
ments in FEV1 in the tiotropium group were maintained 
throughout the trial as compared to placebo (P < 0.001). 
However, after day 30, the differences between tiotro-
pium and placebo in terms of the rate of mean FEV1 
decline before and after bronchodilation were not signifi-
cant. Another important result, was that the number of 
exacerbations per patient-year declined from 0.85 to 0.73 
(P < 0.001) in favour of tiotropium. However, the differ-
ence was not significant for severe exacerbations (0.15 in 
the tiotropium group versus 0.16 in the placebo group) 
(P = 0.34) [17].
SPARK (ClinicalTrials.gov, NCT01120691) [20] was 
a randomised parallel group study investigating the 
relative efficacy of QVA149 (glycopyrronium and inda-
caterol combination) versus glycopyrronium mono-
therapy and tiotropium monotherapy. 2224 patients 
were enrolled, aged 40  years or more, with severe or 
very severe COPD, and one or more moderate COPD 
exacerbations in the last year. Results showed that there 
was no significant difference between glycopyrronium 
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and tiotropium in preventing mild (GLY/TIO RR: 0.99, 
P =  0.90) and moderate or severe (GLY/TIO RR: 1.03, 
P = 0.68) exacerbations. However, in the case of severe 
exacerbations alone, tiotropium was superior to glyco-
pyrronium (GLY/TIO RR: 1.43, P =  0.025). This is the 
relative treatment effect of tiotropium versus glycopyr-
ronium used in the model.
Methods
COPD models
A majority of the cost-effectiveness models in the 
COPD literature are Markov cohort models [6, 22]. 
These types of models are well-suited for modeling 
a chronic and slowly progressing disease like COPD. 
Typically, model health states are constructed around 
the established Global Initiative for Chronic Obstruc-
tive Lung Disease (GOLD) classification of severity 
of airflow limitation [23]. This classification is based 
on four groups; mild (GOLD I FEV1  ≥  80  %), moder-
ate (GOLD II 50  %  ≤  FEV1  <  80  %), severe (GOLD 
III 30  %  ≤  FEV1  <  50  %) and very severe (GOLD IV 
FEV1  <  30  %) COPD, each representing an interval of 
post-bronchodilator FEV1, a measure of airflow [23]. 
COPD develops late in life and its onset is slow. As a 
result, several published models, e.g. [24, 25], assume 
that the cohort begins in the more severe GOLD states, 
where pharmacological therapies are introduced. Some 
models, e.g. [26, 27], also incorporate costs and effects 
of exacerbations. How these events are incorporated 
differs from model to model, but a common practice is 
to model exacerbations as events occurring within the 
health (GOLD) states. This makes it possible to add base-
line costs and outcomes associated with each health state 
as well as additional event-specific costs and outcomes 
associated with exacerbations.
Model description
The Markov cohort model, shown in Fig. 1, was built in 
Treeage Pro Suite 2014. It was based on four health states 
(GOLD II, GOLD III, GOLD IV and DEATH), between 
which the cohort of patients could move with certain 
probabilities. Patients were modelled from the age of 
treatment initiation (65 years old) until they deceased or 
reached the age of 100. Three cohorts were analysed, one 
receiving usual non-LAMA care similar to the placebo 
arm in the UPLIFT trial and two receiving additional 
treatment with either tiotropium 18  µg (Spiriva Han-
diHaler) or glycopyrronium 44  µg (Seebri Breezhaler). 
Upon entering the model, all patients were distributed 
across the separate states according to the observed dis-
tributions found in the UPLIFT trial (GOLD II: 48  %, 
GOLD III: 44  %, GOLD IV: 8  %) [17]. Within each 
three  month cycle the patients could then experience 
any one of the following three events; (1) no exacerba-
tion (2) non-severe exacerbation or (3) severe exacer-
bation. Each event occurred with certain state-specific 
probabilities (risks). Based on trial data from UPLIFT 
and SPARK, these probabilities were varied across the 
treatment alternatives in order to reflect relative efficacy 
of the treatment alternatives. Each state and event com-
bination had different costs and effects associated with 
that particular combination. Subsequent to each event, 
the patients could either die or transition to one of the 
four health states for a new three month cycle to begin. 
The transition probabilities were varied across treatment 
alternatives based on trial data from UPLIFT. In this way, 
a more effective treatment acted to slow down the overall 
progression of disease.
Target patient population
The base case model population was assumed to be simi-
lar to that of the UPLIFT trial in terms of age (65 years), 
disease state (GOLD II–IV), risks of exacerbations 
and the usual care received (non-LAMA). In addi-
tion, to accurately reflect the real world characteristics 
of Swedish COPD patients, the model was populated 
with mortality data representative for a Swedish patient 
population.
Clinical data
Data concerning treatment efficacy, i.e. transition prob-
abilities and relative risks of exacerbations, were mainly 
obtained from the Hettle et al. [28], who in turn derived 
estimates from UPLIFT [17]. Glycopyrronium was 
assumed to be equivalent to tiotropium in terms of 
effect on overall lung function (FEV1). The rationale for 
this assumption is well-founded; recent trials (GLOW1-
2) [29] and indeed SPARK [20], as well as network meta 
analyses [30, 31], have shown comparability in terms of 
the effect on FEV1 between tiotropium and glycopyrro-
nium and other LAMAs. Thus, efficacy data (FEV1) from 
the tiotropium arm of the UPLIFT trial were used to 
model disease progression in both the tiotropium and the 
glycopyrronium cohorts. However, data on relative risks 
of exacerbations for tiotropium versus glycopyrronium, 
were obtained from the SPARK trial. Table 1 provides an 
overview of the sources used to model treatment efficacy.
Hettle et al. [28] derived sets of transition probabili-
ties for tiotropium and usual care arms using data from 
UPLIFT. A separate set of transition probabilities were 
obtained for the first cycle on treatment, in order to 
capture the initial 30-day effect of tiotropium on FEV1 
[28]. In the base case analysis, patients were assumed to 
be on treatment for 4 years from the start of simulation, 
based on the observed treatment duration in UPLIFT 
[17]. The assumption was made to ensure that results 
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were not driven by unrealistic assumptions about treat-
ment duration (some share of patients will in practice 
discontinue treatment). As there is little persistence in 
the effect of LAMAs after stopping treatment, transi-
tion probabilities were assumed to return to the pla-
cebo arm (usual care) probabilities from UPLIFT in the 
cycle after stopping treatment. The sets of transition 
probabilities used in the model are shown in Table  2 
below.
Rates of exacerbations for usual care and tiotropium 
cohorts were obtained from Hettle et  al. [28] (derived 
from UPLIFT [17]) and recalculated to reflect 3  month 
risks. Relative risks of exacerbations for tiotropium ver-
sus glycopyrronium were obtained from SPARK.
Table 3 shows the risks of different types of exacerba-
tions by GOLD state for the different treatment alterna-
tives. In sum, the efficacy of tiotropium versus usual care 
was modelled as a lowering of the risk of exacerbations 
(Table  3) and as a delay in the overall progression of 
COPD (Table 2). The efficacy of tiotropium against glyco-
pyrronium was modelled solely based on the lower risk of 
severe exacerbations (Table 3) found in SPARK.
Fig. 1 Markov model state transition diagram. Within each state a patient can experience any one of the following events: (1) no exacerbation 
(NoEx), (2) non-severe exacerbation (Ex), (3) severe exacerbation (SevEx)
Table 1 Source overview of clinical inputs
a Several trials have shown comparable efficacy between tiotropium and glycopyrronium in terms of overall lung function (FEV1)
b As there is little persistence in the effect of LAMAs after stopping treatment, transition probabilities were assumed to return to the placebo arm (usual care) 
probabilities in the cycle after stopping treatment
c Applied to baseline risks of exacerbations from UPLIFT (TIO arm)
Clinical input Usual care Tiotropium Glycopyrronium
Transition probabilities
 Cycles on treatment (year 0–4) UPLIFT (UC arm) UPLIFT (TIO arm) UPLIFT (TIO arm)a
 Cycles off treatment (year 4–>) UPLIFT (UC arm) UPLIFT (UC arm)b UPLIFT (UC arm)b
Probabilities of exacerbations
 Baseline risks of exacerbations UPLIFT (UC arm) UPLIFT (TIO arm) UPLIFT (TIO arm)
 Relative risks 1.00 N/A (probs applied) SPARK RR TIO/GLYc
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Epidemiological data
Age-differentiated mortality rates were derived for each 
GOLD state (II–IV). Excess mortality rates associated 
with events were derived in the case of severe exacerba-
tions, but not in the case of “non-severe exacerbations” 
or “no exacerbations”, for which the state-specific mortal-
ity rates were assumed to hold.
Mortality rates for health states and severe exacerba-
tions were comprised of two separate parts; (1) baseline 
age-differentiated mortality for the general population in 
Sweden in 2012, and (2) excess mortality associated with 
the state or event in question. Baseline age-differentiated 
mortality for the general population in 2012 was obtained 
from the National Board of Health and Welfare (Social-
styrelsen) and its database on causes of deaths [32]. From 
the database it was possible to discern the share of total 
deaths that were related to COPD (ICD-10: J44) and to 
factor these out of the baseline mortality rates. The cor-
rected and age-differentiated mortality rates for the 
general population were then used as baseline rates, on 
top of which excess mortality rates were added. Point 
estimates for excess mortality associated with each 
GOLD state were obtained from Garcia-Aymerich et al. 
[10] and extrapolated over age intervals using the change 
in relative risk between age groups from Hoogendoorn 
et  al. [33]. Similarly, age-differentiated excess mortal-
ity rates for severe exacerbations were generated using 
point estimates and changes in relative risks between age 
groups from Hoogendoorn et al. [33].
Health economic data
The analysis takes on a societal perspective. However, 
because the start age was set to 65 years in the base case, 
i.e. equal to the retirement age in Sweden, indirect costs 
were deemed to be negligible and thus only direct costs 
were considered in this model. Direct costs were assigned 
for the different state-event combinations using data 
from two different studies of Swedish COPD patients [5, 
34]. Three month COPD maintenance costs, e.g. costs 
of drugs, outpatient care, oxygen therapy and other 
non-exacerbation related direct costs, were obtained 
from Jansson et  al. [5]. Costs of non-severe and severe 
Table 2 Model transition probabilities by GOLD states
Source: [28] (derived from [17]). For tiotropium and glycopyrronium cohorts, usual care probabilities were assumed to hold when off treatment. Probabilities have 
been recalculated to reflect three month probabilities. Death has been excluded, as this model carries separate mortality rates derived for a Swedish population
Usual care First cycle Subsequent treatment cycles
TO TO
GOLD II GOLD III GOLD IV GOLD II GOLD III GOLD IV
FROM
 GOLD II 0.86 0.13 0.01 0.91 0.09 0.00
 GOLD III 0.13 0.81 0.06 0.08 0.88 0.04
 GOLD IV 0.02 0.22 0.76 0.00 0.13 0.87
Tiotropium/glycopyrronium First cycle Subsequent treatment cycles
TO TO
GOLD II GOLD III GOLD IV GOLD II GOLD III GOLD IV
FROM
 GOLD II 0.92 0.08 0.00 0.92 0.08 0.00
 GOLD III 0.17 0.80 0.03 0.08 0.88 0.04
 GOLD IV 0.03 0.28 0.69 0.00 0.12 0.88
Table 3 Model probabilities of exacerbations by GOLD states
Source: [28] (derived from [17]), [20] and own calculations to reflect three month probabilities
GOLD Usual care Tiotropium Glycopyrronium
II III IV II III IV II III IV
No exacerbation 0.84 0.78 0.73 0.87 0.81 0.77 0.86 0.79 0.74
Non-severe exacerbation 0.14 0.17 0.18 0.11 0.14 0.15 0.11 0.14 0.14
Severe exacerbation 0.02 0.05 0.08 0.02 0.05 0.08 0.03 0.07 0.12
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exacerbations, from Andersson et al. [34], were added to 
the maintenance costs to obtain the total cost for each 
state-event combination. Table  4 shows the direct costs 
per cycle used in the model.
As in the case of costs, separate utility weights were 
assigned to the different state-event combinations. The 
baseline utility weights for each GOLD state were obtained 
from a Swedish study, Ståhl et al. [35]. Decrements associ-
ated with non-severe exacerbations (1.66  %) and severe 
exacerbations (4.82  %) were obtained from Hoogendorn 
et al. [33]. The decrements were applied to the annual util-
ity weights, thus making it a conservative assumption of the 
utility loss of exacerbations. Table 5 shows the annual utility 
weights associated with each state-event combination.
Model validation
The model was thoroughly validated. Cohort transi-
tion matrices for the distribution of GOLD states as 
well as the predicted risks of exacerbations were repro-
grammed in Excel and compared with similar outputs 
in the TreeAge model. Both approaches showed the 
same results. The annualised rates of severe exacerba-
tions predicted by the model in a 4 year simulation (the 
length of UPLIFT) were very close to those of Hettle et al. 
[28] (Hettle et  al. SevEx: UC, 0.22; TIO, 0,21—Cohort 
model SevEx: UC, 0.24; TIO, 0.22). The difference can be 
explained by different mortality rates used in our model 
compared to the Hettle et al. [28] model.
Base case analysis
In base case, cost-effectiveness of tiotropium was com-
pared to usual care and to glycopyrronium. The assump-
tions made in the base case analysis are shown in Table 6.
Sensitivity analysis
Uncertainty was assessed both through deterministic and 
probabilistic sensitivity analysis (PSA). Extensive one-
way deterministic sensitivity analyses were performed 
on key model parameters, in order to assess their impact 
on the main result (ICER). Different subgroups of inter-
est were also assessed, e.g. males and females only as well 
as patients with moderate, severe and very severe COPD 
respectively.
Probabilistic sensitivity analysis was performed rela-
tive to the two comparators separately using Monte 
Carlo simulation (10,000 iterations). Distributions were 
assigned to key model inputs; treatment effect on exac-
erbations (lognormal), direct costs (uniform) and util-
ity weights (uniform). The uncertainty of the treatment 
effect on non-severe and severe exacerbations was 
assessed using the 95  % confidence intervals from the 
respective studies. Uncertainty of direct costs and utility 
weights were modelled using a uniform distribution and 
±20 % interval around the point estimates.
Results
Base case
Base case results from the comparison between tiotro-
pium and usual care are presented in Table 7. Tiotropium 
added 0.07 QALYs and 0.08 life years compared to usual 
care alone. In addition, tiotropium increased total costs 
by SEK 15,041 over the lifetime of the average patient. 
The resulting incremental cost-effectiveness ratio (ICER) 
was SEK 224,850.
Base case results from the comparison between tiotro-
pium and glycopyrronium are presented in Table 8. Tio-
tropium added 0.23 QALYs and increased total costs by 
Table 4 Direct costs (SEK 2014) by  GOLD state and  type 
of event
Source: maintenance costs by GOLD-state from [5], exacerbation costs from [34]. 
Costs for mild and moderate exacerbations were merged to form non-severe 
exacerbations
GOLD II GOLD III GOLD IV
No exacerbation 1284 3032 4297
Non-severe exacerbation 4423 6170 7436
Severe exacerbation 27,817 29,564 30,830
Table 5 Utility weights by GOLD state and type of exacer-
bation
Source: baseline utility weights (no exacerbation) [35], annual utility decrements 
[33]
GOLD II GOLD III GOLD IV
No exacerbation 0.73 0.74 0.52
Non-severe exacerbation 0.72 0.73 0.51
Severe exacerbation 0.69 0.70 0.49
Table 6 Base case inputs and assumptions
Variable Description References
Time horizon Life time Assumption
Start age 65 years Based on [17] (mean)
Sex Both Assumption
Treatment duration 4 years Based on [17] length
Cost of tiotropium SEK 12.77 per day [36]
Cost of glycopyrronium SEK 10.48 per day [36]
Discount rate 3 % per annum (both 
effects and costs)
[37]
Initial prob GOLD II: 48 %, GOLD III: 
44 %, GOLD IV: 8 %
[17]
Transition prob Probabilities (3-month) [28]
Mortality states GOLD, age and sex 
dependent
[10, 32, 33]
Mortality severe ex Excess mort increasing 
with age
[33]
Exacerbation risks Probabilities (3-month) [20, 28]
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SEK 2423 compared to glycopyrronium. The resulting 
ICER amounted to SEK 10,456.
Sensitivity analysis
Deterministic sensitivity analysis
Figures 2, 3 and Table 9 show how the ICER was affected 
when varying key model parameters one at a time. The 
parameters that impacted the ICER the most were time 
horizon and the treatment effect on severe exacerbations 
(RR SevEx). In a realistic scenario with a life-long time 
horizon, the treatment effect on severe exacerbations 
was by far the most important parameter. In the case of 
tiotropium versus usual care, applying the 95 % CI lower 
limit for the rate of severe exacerbations from Hettle 
et al. [28] substantially increased the ICER. In the case of 
tiotropium versus glycopyrronium, applying the 95 % CI 
lower limit for RR SevEx 1.05 (base case 1.43) increased 
the ICER to SEK 115,000, which would still be consid-
ered highly cost-effective. In fact, tiotropium remains 
cost-effective at current willingness-to-pay thresh-
olds (SEK  ~  600,000) even when RR SevEx is as low as 
1.02–1.03.  
Probabilistic sensitivity analysis
Figures  4 and 5 show the cost-effectiveness acceptabil-
ity curves for both comparators relative to tiotropium. 
Tiotropium is highly cost-effective (TIO vs UC: 80 %/TIO 
vs GLY: 90 %) at the implicit willingness-to-pay threshold 
for Sweden (SEK ~ 600,000). 
Discussion
The primary objective of this study was to assess the 
cost-effectiveness of tiotropium when added to usual 
non-LAMA care compared to usual care alone in a 
population relevant for a Swedish setting. The second-
ary objective was to compare the cost-effectiveness of 
tiotropium relative to glycopyrronium under similar 
circumstances. Tiotropium was found to be highly cost-
effective relative to both comparators at current implicit 
WTP thresholds in Sweden. The results were to a large 
extent driven by the relative efficacy in preventing 
severe exacerbations.
The results when comparing tiotropium to usual 
care are in line with those found in Hettle et  al. [28], 
from which some of the data used in this study has 
been obtained. Hettle et  al. estimated a cost per QALY 
gained of around £16,000 (SEK 170,000) in a UK set-
ting in 2012. Considering the different cost structures 
and patient populations in UK and Sweden, the number 
is not too far astray from the cost per QALY gained of 
SEK 224,850 found in this study. From a broader per-
spective, the results found in this study are in line with 
overall results found in other cost-effectiveness studies 
of bronchodilators. Mauskopf et  al. [38], a systematic 
review of 17 cost-effectiveness studies, found that tiotro-
pium monotherapy was either cost-saving or highly cost-
effective compared to other non-LAMA bronchodilator 
monotherapies. Similarly, Van Mölken et  al. [22], a sys-
tematic review of 40 cost-effectiveness studies, concluded 
that all studies assessing tiotropium treatment, reported 
beneficial health effects of tiotropium versus placebo, 
ipratropium or salmeterol, sometimes even at a reduc-
tion in total COPD-related healthcare costs. In light of 
these findings and the findings of this study this suggests 
that tiotropium is highly cost-effective compared to usual 
non-LAMA care also in Sweden.
When comparing tiotropium monotherapy to other 
LAMA monotherapies, e.g. glycopyrronium, there are 
few published cost-effectiveness studies at this point to 
compare results to. Efficacy estimates from GLOW1-2 
and SPARK studies suggest that tiotropium and glyco-
pyrronium are equivalent in terms of overall lung func-
tion (FEV1). Thus, cost-effectiveness is likely to be highly 
dependent on the ability to prevent exacerbations, par-
ticularly severe ones that lead to costly hospitalisations. 
Using the results from the SPARK study which was 
favourably designed to detect exacerbations, this study 
has shown that, given the best available evidence on 
exacerbation prevention to date (SPARK), the balance 
Table 7 Base case results—tiotropium vs usual care
All costs and effects discounted at an annual rate of 3 %
UC TIO TIO–UC
Costs (SEK 2014)
 Treatment costs 0 17,315 17,315
 Direct costs 167,654 165,380 −2274
 Total costs 167,654 182,695 15,041
Health outcomes
 QALYs 7.18 7.25 0.07
 Life years 10.18 10.26 0.08
ICER 224,850
Table 8 Base case results—tiotropium vs glycopyrronium
All costs and effects discounted at an annual rate of 3 %
GLY TIO TIO–GLY
Costs (SEK 2014)
 Treatment costs 13,965 17,315 3351
 Direct costs 166,308 165,380 −928
 Total costs 180,272 182,695 2423
Health outcomes
 QALYs 7.02 7.25 0.23
 Life years 9.93 10.26 0.33
ICER 10,456
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Fig. 2 Tornado diagram ICER (TIO vs UC)
Fig. 3 Tornado diagram ICER (TIO vs GLY)
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would likely sway in favour of tiotropium being a more 
cost-effective alternative to glycopyrronium.
Extensive sensitivity analyses were conducted to assess 
the impact of key parameters on the main results. The 
relative efficacy of the interventions, particularly in pre-
venting severe exacerbations, played an important role in 
explaining cost-effectiveness. In this regard, it is impor-
tant to remember the basic design and purpose of the 
Table 9 One-way sensitivity analysis (ICER in SEK 2014)
“Dominating” tiotropium is dominating, “dominated” tiotropium is dominated
Base case: RR SevEx GLY vs TIO = 1.43
a TIO vs UC, Hettle et al.; TIO vs GLY, RR SevEx in SPARK 1.43 (CI 1.05–1.97, P: 0.025)
Variable of interest Value TIO vs UC TIO vs GLY
Base case 224,850 10,456
Discount rate 0 % 187,684 13,206
5 % 249,658 8523
Time horizon 5 years 592,149 Dominat-
ing
10 years 326,192 2233
20 years 235,715 9641
Treatment duration 1 year 102,727 9849
10 years 294,652 12,081
Life (35 years) 330,299 14,962
Sex Males only 230,862 9646
Females only 220,021 11,141
Start age 40 320,470 2119
80 240,894 11,043
GOLD start dist All start in GOLD II 225,925 12,878
All start in GOLD III 224,903 9172
All start in GOLD IV 217,926 7084
Mortality Normal mortality (not adjusted for COPD) for all GOLD states 232,402 11,522
20 % higher excess mortality (Sev Ex) 204,979 12,424
20 % lower excess mortality (Sev Ex) 247,036 8093
Effect of tiotropium on Sev Ex Low 95 % CI from studiesa (RR Sev Ex) 103,232 114,589
High 95 % CI from studiesa (RR Sev Ex) 5,845,054 2859
Direct costs of Sev Ex 20 % higher 221,336 5665
20 % lower 228,367 15,246
QoL loss of Sev Ex exacerbations 0 % loss 225,934 10,528
20 % loss 221,429 10,235
Fig. 4 Cost-effectiveness acceptability curve for TIO vs UC Fig. 5 Cost-effectiveness acceptability curve for TIO vs GLY
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UPLIFT and SPARK trials and how these factors poten-
tially affected the results. The purpose of the UPLIFT trial 
was to assess the effect of the interventions on overall 
lung function; exacerbations were only a secondary objec-
tive. Additionally, the patients received usual non-LAMA 
care in both arms. This included LABA and/or corticos-
teroid therapy in a majority of the patients enrolled. The 
trial not being primarily designed to detect exacerbations 
and the use of alternative inhaled therapy, likely affected 
rates of exacerbations downwards. This may explain why 
the study found no significant difference in the rates of 
severe exacerbations between the two arms.
As opposed to the UPLIFT trial, the SPARK trial was 
designed specifically to detect moderate and severe exac-
erbations. High risk patients, i.e. those having had at least 
one moderate exacerbation in the past year, were enrolled 
and randomly assigned to receive either QVA149 
(LAMA/LABA combination), tiotropium or glycopyr-
ronium. Importantly, patients that were receiving LABA 
therapy, discontinued the therapy upon enrolling in the 
trial, although ICS therapy continued. Indeed, these cir-
cumstances suggest that the SPARK trial was favourably 
designed to detect and record exacerbations. Having said 
that, there were only 364 severe exacerbations reported in 
total across all three arms in SPARK. The low number of 
observed severe exacerbations naturally introduces some 
uncertainty in the estimate of the relative risk between 
tiotropium and glycopyrronium and therefore also 
increases the uncertainty of cost-effectiveness results. It 
is however important to keep in mind that, as opposed to 
mild and moderate exacerbations, severe exacerbations 
are infrequent events in COPD. In addition, SPARK did 
not include a placebo arm, which means that all arms in 
the trial contained active therapy with the specific aim 
of lowering rates of exacerbations. These circumstances 
suggest that even if a trial is favourably designed to detect 
severe exacerbations, it is always going to be difficult to 
amass a large study population to record enough severe 
exacerbations. Future research should nevertheless con-
tinue to focus efforts on disentangling the relative effi-
cacy of different types of bronchodilators in preventing 
these rare events, as they are important factors explain-
ing morbidity, mortality and cost-effectiveness in COPD.
Finally, a potential drawback with this study, like any 
other utilising trial data, is that the patient population 
might be somewhat different from the actual population 
of COPD patients (GOLD II–IV) in Sweden. Measures, 
such as incorporating baseline mortality rates for Swe-
den, were taken to limit this potential bias.
Conclusion
Using data from UPLIFT and SPARK studies, and 
explicitly modelling the effects of exacerbations, the 
cost-effectiveness of tiotropium when added to usual 
(non-LAMA) care was assessed relative to usual (non-
LAMA) care alone. A second comparison assessed the 
cost-effectiveness of tiotropium relative to glycopyrro-
nium (another LAMA). Tiotropium was deemed to be 
highly cost-effective relative to both comparators at cur-
rent willingness-to-pay thresholds in Sweden. The find-
ings were mainly driven by tiotropium being a relatively 
efficacious intervention in preventing exacerbations, par-
ticularly severe ones that lead to hospitalisations.
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